Greywolf Therapeutics
Greywolf Therapeutics is a biotechnology company developing small molecule treatments that modulate antigen presentation to help T cells recognize and target diseased cells. The company has raised $122M, most recently in a Series B round in May 2024, and employs 57 people.
The growth story
Greywolf Therapeutics grew from 9 to 57 employees between 2021 and 2026, raising $122M along the way, most recently a Series B in May 2024.
About
Greywolf Therapeutics creates small molecule drugs that alter how cells appear to the immune system, enabling T cells to better recognize and attack diseased cells. Its lead oncology treatment GRWD5769 has shown promising Phase 1/2 results in solid tumors, while its autoimmunity treatment GRWD0715 is in Phase 1/2 trials for axial spondyloarthritis.
The company has raised $122M across funding rounds, including a Series B in May 2024 backed by investors like Andera Partners and Oxford Science Enterprises. With 57 employees, Greywolf draws heavily from pharmaceutical industry veterans, particularly from Pfizer and GSK.
Founders and leadership
Operations is Greywolf's largest function with 7 employees. The company has a median tenure of 2 years, suggesting relatively stable staffing despite its rapid growth since its 2017 founding.
The Greywolf Therapeutics org chart
Peter Joyce (CEO and Founder) leads 35 mapped leaders with 3 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 11 (-15% YoY), Business Development 10 (0% YoY), Program and Project Management 8 (0% YoY), Operations 7 (+75% YoY), Finance 4 (+100% YoY), Information Technology 3 (0% YoY).
Talent flow
Greywolf recruits heavily from major pharma companies, with Pfizer and GSK each contributing 6 hires. Its alumni have moved to roles at Molecule to Medicine, Myrtle Advisory, and Deep Science Ventures.
Most common previous employers of Greywolf Therapeutics staff: Pfizer (6), GSK (6), Amgen (4), Molecule to Medicine (4), Adaptimmune (4), invoX (3). Former Greywolf Therapeutics employees most often moved to Molecule to Medicine (3), Myrtle Advisory (1), Deep Science Ventures (1), SERB Pharmaceuticals (1), Rubicom Services (1), M Ventures (1).
Alumni worth knowing
Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at Greywolf Therapeutics: Pharmaceutics (20), Project Management (20), Biotechnology (17), Life Sciences (15), Communication (15), Research Skills (15), Oncology (14), Drug Development (14).
Where the team actually sits
Greywolf Therapeutics people are concentrated in England, United Kingdom (31), United Kingdom (6), Greater Oxford Area (5), Victoria, Australia (3). 2 offices on record.
Search footprint
Greywolf Therapeutics attracts about 48 organic search visits a month, traffic worth roughly $1K a month if bought through ads. It gained 31 ranking keywords and lost 16 in the last period.
Frequently asked
Greywolf Therapeutics has 57 employees as of September 2026.
Greywolf Therapeutics has raised $122M in total, most recently a Series B round in May 2024.
Greywolf Therapeutics was founded in 2017 by Peter Joyce, Tom McCarthy.
Peter Joyce (CEO and Founder) sits at the top of Greywolf Therapeutics's reporting structure, with 3 direct reports.
The most common previous employers of current Greywolf Therapeutics staff are Pfizer (6 people), GSK (6 people), Amgen (4 people).
Former Greywolf Therapeutics employees most often move to Molecule to Medicine (3), Myrtle Advisory (1), Deep Science Ventures (1).
Greywolf Therapeutics attracts about 48 organic search visits a month, worth roughly $1K a month in equivalent ad spend.
The most common skills among Greywolf Therapeutics staff are Pharmaceutics, Project Management, Biotechnology, Life Sciences, Communication.
Greywolf Therapeutics staff are concentrated in England, United Kingdom (31), United Kingdom (6), Greater Oxford Area (5).
Greywolf Therapeutics has about 11 people in Research, down 15% over the past year, as of September 2026.
Greywolf Therapeutics has about 10 people in Business Development, up 0% over the past year, as of September 2026.
Computed from 49 current and 22 former Greywolf Therapeutics profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.